Biomark X Offers Industry-Leading Advantages in Speed, Throughput, Flexibility and Cost
November 11 2021 - 8:30AM
Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology
tools provider with a vision to improve life through comprehensive
health insight, today announced the launch of Biomark™ X, the
latest generation of its industry-leading Biomark microfluidics
platform. Biomark X integrates the Fluidigm® Juno™ and Biomark HD
instruments into a single platform while adding an expansive set of
sample-to-answer capabilities on a single versatile, scalable and
transformative genomics platform.
Biomark X simplifies workflows, streamlines operations to reduce
hands-on time, and accelerates results with more data per run.
“Accurate and reproducible data is essential for discovery and
applied research applications that utilize real-time PCR,” said
Chris Linthwaite, President and CEO. “Today we are taking our
formidable microfluidics platform to the next level with Biomark X,
minimizing hands-on time and allowing researchers to focus on the
key questions that matter most. The system can significantly reduce
labor costs and provides a rapid sample-to-answer capability, which
is increasingly critical across the genomic testing landscape.
“We believe Biomark X will be invaluable to a broad range of
customers, including current and future partners, encompassing
pharmaceutical, contract research organization and academic labs,
while delivering a next-generation solution for clinical research
labs that are on the front lines fighting diseases and emerging
pathogens,” said Linthwaite. “Biomark X offers multiple value
propositions to maximize the value Biomark X brings to our
customers, and we are offering a concierge program for
customization of workflows. We welcome inbound inquiries to expand
our growing networks of partners.”
“The subject of a phased launch with deliveries expected to
commence in the first quarter of 2022, Biomark X is the latest
product introduction aligning with our Vision 2025 innovation
objectives, coming just five months after the launch of CyTOF® XT,
the fourth-generation platform using our pioneering CyTOF
technology. We are immensely proud of the role we expect both of
these advanced platforms to play in answering today’s most
important questions in biology and human health.”
Biomark X is an intuitive and integrated system that performs a
variety of tasks, including genotyping, sample ID, strain ID,
conservation biology, personal genomics, gene expression, pathogen
detection, pharmacogenomics assays, and transplant prognostics.
The new platform supports development and creation of custom
assays, providing a wide range of testing and investigation options
and the ability to scale the number of targets based on need.
Learn more: fluidigm.com/biomarkx
About FluidigmFluidigm (Nasdaq: FLDM)
focuses on the most pressing needs in translational and clinical
research, including cancer, immunology, and immunotherapy. Using
proprietary CyTOF and microfluidics technologies, we develop,
manufacture, and market multi-omic solutions to drive meaningful
insights in health and disease, identify biomarkers to inform
decisions, and accelerate the development of more effective
therapies. Our customers are leading academic, government,
pharmaceutical, biotechnology, plant and animal research, and
clinical laboratories worldwide. Together with them, we strive to
increase the quality of life for all. For more information,
visit fluidigm.com.
Fluidigm, the Fluidigm logo, Biomark, CyTOF, CyTOF XT,
and Juno are trademarks and/or registered trademarks
of Fluidigm Corporation or its affiliates in the
United States and/or other countries. Fluidigm products,
including Biomark X, are provided for Research Use Only. Not for
use in diagnostic procedures.
Forward-Looking Statements for
Fluidigm This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including, among others, statements regarding
the launch of and anticipated demand for a new product, as well as
the anticipated benefits to customers of, and applications for, the
product and other Fluidigm products. Forward-looking statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from currently anticipated results,
including but not limited to risks relating to challenges inherent
in developing, manufacturing, launching, marketing, and selling new
products; potential product performance and quality issues;
intellectual property risks; competition; uncertainties in
contractual relationships; and reductions in research and
development spending or changes in budget priorities by customers.
Information on these and additional risks and uncertainties and
other information affecting Fluidigm business and
operating results is contained in Fluidigm’s Annual Report on Form
10-K for the year ended December 31, 2020, and in its other
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date
hereof. Fluidigm disclaims any obligation to update these
forward-looking statements except as may be required by law.
Available InformationWe use our website,
investor site, corporate Twitter account, Facebook page, and
LinkedIn page as channels of distribution of information about our
products, our planned financial and other announcements, our
attendance at upcoming investor and industry conferences, and other
matters. Such information may be deemed material information, and
we may use these channels to comply with our disclosure obligations
under Regulation FD. Therefore, investors should monitor our
website and our social media accounts in addition to following our
press releases, SEC filings, public conference calls, and
webcasts.
Fluidigm
Media:Mark SpearmanSenior Director, Corporate
Communications650 243 6621mark.spearman@fluidigm.com
Investors:Peter DeNardo415 389 6400
ir@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Sep 2023 to Sep 2024